About US
Contact us
-
GSK faces criminal investigation over bribery allegations in PolandUK-based drug manufacturer GlaxoSmithKline (GSK) is facing allegations of bribing doctors to promote its asthma drug Seretide in Poland's Lodz region. The issue, reported by BBC on its Panorama progr2014/4/16
-
Impax Pharma resubmits NDA to FDA for Parkinson's treatment RytaryImpax Laboratories division Impax Pharmaceuticals has resubmitted its new drug application (NDA) for Rytary (IPX066) to the US Food and Drug Administration (FDA) for treatment of patients with Parkins2014/4/15
-
Tetra and Stanley Center collaborate to discover next generation of schizophrenia drugsUS-based Tetra Discovery Partners entered into a drug development collaboration with the Broad Institute's Stanley Center for Psychiatric Research in Cambridge, Massachusetts. The deal is focused on2014/4/15
-
Alcobra submits protocol to US FDA for Phase IIb MDX trial to treat Fragile X SyndromeIsrael-based biopharmaceutical firm Alcobra has submitted a protocol to the US Food and Drug Administration (FDA) for a Phase IIb clinical trial of its proprietary drug candidate Metadoxine Extended R2014/4/14
-
Pharmacyclics submits sNDA to FDA for leukaemia drug ImbruvicaPharmacyclics, collaboration partner of Janssen Research & Development (Janssen), has submitted a supplemental new drug application (sNDA) for Imbruvica (ibrutinib) to the US Food and Drug Adminis2014/4/14
-
Eli Lilly and T1D Exchange partner to support type 1 diabetes patientsEli Lilly and Company and T1D Exchange have entered into a research collaboration to discover new ways to improve care and advance outcomes for patients with type 1 diabetes (T1D). The collaboration2014/4/11
-
FDA grants priority review for Gilead's hepatitis C combination therapyThe US Food and Drug Administration (FDA) has granted priority review to Gilead Sciences' new drug application (NDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90mg2014/4/11
-
Scottish Medicines Consortium issues positive advice for Actelion's PAH drug OpsumitActelion Pharmaceutical UK's new endothelin receptor antagonist Opsumit (macitentan) is now available through NHS Scotland as monotherapy or in combination, for the long-term treatment of pulmonary ar2014/4/10
-
FDA grants priority review for Gilead's hepatitis C combination therapyThe US Food and Drug Administration (FDA) has granted priority review to Gilead Sciences' new drug application (NDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90mg2014/4/10
-
Merck, Ferring and WHO team-up for new anti-bleeding drugMerck and Ferring Pharmaceuticals have entered into collaboration with the World Health Organization (WHO) to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding (2014/4/9